Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Grazax in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Boys and girls 5-16 years of age~* A clinical history of grass pollen induced hayfever~* Positive Skin Prick Test to Phleum pratense~* Positive specific IgE against Phleum pratense~Exclusion Criteria:~* History of seasonal hayfever symptoms (and/or asthma) caused by another allergen than Phleum pratense during or overlapping the grass pollen season~* History of perennial hayfever (and/or asthma) that needs medication due to an allergen to which the child is regularly exposed~* History of severe asthma~* Current severe atopic dermatitis

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Grazax treatment
- 2 (Type: PLACEBO_COMPARATOR): Grazax Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).